Leukemia Clinical Trials in San Antonio

Showing 241-260 of 564 trials

ACTIVE_NOT_RECRUITINGPHASE1/PHASE2< 1 mile

A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)

NCT05885464

This is a Phase 1/2, multicenter, open-label study to evaluate the safety and efficacy of BEAM-201 in patients with relapsed/refractory T-ALL or T-LL. This study consists of Phase 1 dose-exploration cohorts, Phase 1 dose-expansion cohort(s), a Phase 1 pediatric cohort (will enroll patients ages 1 to \< 12 years), and a Phase 2 cohort.

Lymphoblastic LymphomaT-Cell Lymphoblastic Leukemia/LymphomaLymphoblastic Leukemia

Beam Therapeutics Inc.5 participantsStarted May 2023

Stanford, California, United States • Denver, Colorado, United States • Chicago, Illinois, United States +7 more locations

ENROLLING_BY_INVITATIONPHASE1< 1 mile

Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T

NCT04488354

This study is designed as a long-term follow-up study of participants who have receive genetically modified autologous CLBR001 CAR-T cells

Relapsed/Refractory B-cell LymphomasDiffuse Large B-Cell Lymphoma (DLBCL)Follicular Lymphoma (FL)+9 more

Calibr, a division of Scripps Research36 participantsStarted Jan 2021

Duarte, California, United States • San Diego, California, United States • Chicago, Illinois, United States +5 more locations

A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)

Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T

Leukemia Trials in Other Cities

Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel

A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents

Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia

A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies

Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1

Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer

Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors

A Study of ZN-c3 in Patients With Ovarian Cancer

A Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-3)

Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers

Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies

MIRACLE of LIFE Study

Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789)

A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations

A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet Chemotherapy

A Long-Term Safety Follow-Up Study for Patients Treat With WU-CART-007

Carboplatin and Paclitaxel With or Without Vorinostat in Treating Patients With Advanced Non-Small Cell Lung Cancer

A Study Investigating the Safety, Tolerability and Efficacy of ASP7517 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS)

Other Conditions in San Antonio